BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is highlighted as one of the 7 Oversold Pharma Stocks to Buy Now, with Evercore ISI identifying long-term growth potential. The recent acquisition of Astria Therapeutics positions BCRX for success, with Orladeyo projected to reach $900 million in peak sales by 2029 and Navenibart to generate $1 billion in revenue.

BCRX announced nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting, highlighting real-world and clinical trial outcomes for ORLADEYO and Navenibart. Results from the ALPHA-SOLAR trial show sustained HAE attack suppression with dosing every three or six months, demonstrating the efficacy of these therapies.

As a biopharmaceutical company, BCRX focuses on developing oral and small-molecule therapies for rare diseases and serious conditions, including antiviral and complement system disorders. While BCRX shows investment potential, other AI stocks may offer greater upside and less downside risk, with a free report available for those interested in undervalued AI stocks.

For more news on unstoppable dividend stocks and high-yielding stocks, check out the latest articles. Disclosure: None.

Read more at Yahoo Finance.: Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition